The SAVE Trial: Securing All IntraVenous Devices Effectively In Hospitals. A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$980,393.00
Summary
Going to hospital usually means having an IV drip in your hand or arm vein. Almost half of all IV drips fall out or fail because they are not well secured to the skin. This means patients miss out on treatment and have additional painful needlesticks to insert new devices. Serious infections can also occur. This study will find the best dressings to use on IV drips. Patients will have their drips glued in with medical superglue, or have one of two new dressings, compared with current usual care.
Intravascular Device Administration Sets: Replacement After Standard Versus Prolonged Use (The RSVP Trial)
Funder
National Health and Medical Research Council
Funding Amount
$1,611,239.00
Summary
Most hospital patients need an IV drip, a small plastic tube in a vein, often the hand/arm. 14 million/yr are used in Australia. IV drips are connected to plastic tubing through which fluid & medicine is given. IV tubing is needed for a week or more, but is only used for 3-4 days as it was thought this might prevent infection. It is now thought that IV tubing can be used for a week. This would save $1 billion/year & reduce nurses workload. The research will test the safety of this approach.
CareTrack Aged: Appropriate Care Delivered To Australians Living In Residential Aged Care
Funder
National Health and Medical Research Council
Funding Amount
$1,157,722.00
Summary
Given Australia’s rapidly ageing population, keeping up with future demands and maintaining quality of care in residential aged care facilities (RACF) is vital. This study will assess whether care delivered is consistent with the evidence in 15 conditions that are frequently managed in RACFs. These will include delirium, dementia, depression, pain management and medication management. We will also assess the quality of life of residents in RACFs.
Evaluation Of SCID-I In The Diagnosis Of Mental Disorders In Indigenous Australians
Funder
National Health and Medical Research Council
Funding Amount
$988,007.00
Summary
Current estimates of mental disease among Indigenous Australians are inadequate. This research will examine the use of a structured interview tool that is promoted globally for diagnosing mental disorders, and then use the tool to quantify the burden of mental illness among Indigenous Australians. The findings will provide accurate estimates of occurrence of mental disorders, thereby help inform policy making and planning of services for Indigenous Australians.
INTroducing A Care Bundle To Prevent Pressure Injury (the INTACT Trial)
Funder
National Health and Medical Research Council
Funding Amount
$1,093,250.00
Summary
In Australia, hospital acquired pressure injuries (i.e. bedsores) range from 7.4% – 17.4%. A care bundle is a structured group of interventions associated with improved patient outcomes. The aim of this 3-year cluster randomised controlled trial is to provide rigorous evidence regarding the effect of a patient centred pressure injury prevention care bundle on the development of pressure injuries in patients at risk of developing a hospital acquired pressure injury.
ADding Negative PRESSure To Improve HealING (the DRESSING Trial)
Funder
National Health and Medical Research Council
Funding Amount
$2,380,446.00
Summary
The aim of this 5-year randomised comtrolled trial is to test the clinical and cost effectiveness of vacuum dressings in reducing the incidence of surgical site infection in obese women undergoing elective and semi-urgent caesarian section. The trial will be conducted at 4 hospitals in south east Queensland. 2,100 women undergoing caesarian section will either receive a vacuum or standard surgical dressing and will be followed for 1 month after surgery.
Which Heart Failure Intervention Is Most Cost Effective In Reducing Hospital Care (WHICH? II) Trial: A Multicentre, Randomised Trial Of Standard Versus Intensified Management Of Metropolitan And Regional-dwelling Patients With Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$1,891,210.00
Summary
Chronic heart failure (CHF) management programs are now the gold-standard to cost-effectively care for thousands of Australians hospitalised with CHF each year. We’ve shown that home-based management is most cost-effective in reducing hospital stay in CHF. The Which Intervention is most Cost-effective in reducing Hospital care (WHICH? II) Trial, a multicentre, randomised study, will determine if more intensive care (via home visits and remote care contacts) further improves poor outcomes in CHF.
Clinical And Psychosocial Changes Over Late Childhood And Adolescence And Early Life Determinants Of Long Term Clinical Outcomes In Cystic Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$1,135,570.00
Summary
Cystic fibrosis is the most common life shortening inherited disease in Caucasians. Lung damage starts in infancy and lung function falls most rapidly in adolescence although why and how this happens and early life determinants are not known. This study takes advantage of a previous study that monitored young children from 3 months to 5 years of life and follows them closely through early adolescence to investigate the protective and risk factors for falling lung function.
Probiotic Prawn Oral Immunotherapy (ProPIT) For Treatment Of Prawn Allergy
Funder
National Health and Medical Research Council
Funding Amount
$1,865,369.00
Summary
A ‘curative’ food allergy treatment is needed to prevent deaths and improve care. We recently showed that probiotic peanut oral immunotherapy (PPOIT) was highly effective for treating peanut allergy. 82% of PPOIT treated children gained tolerance compared to 4% of the placebo group. We will now test the combined probiotic-food OIT approach for treating prawn allergy. If successful, we will have identified the first treatment for prawn allergy and a platform treatment for other food allergies.
Improving Oesophageal Adenocarcinoma Outcomes Through Understanding Genomics And Treatment Toxicity.
Funder
National Health and Medical Research Council
Funding Amount
$1,013,282.00
Summary
Oesophageal adenocarcinoma is an aggressive cancer, as most patients will not survive for more than 5 years. Therefore we need to find better ways to treat patients. In this study we will identify the DNA mutations in oesophageal cancers that were part of clinical trial. The data allow us to determine why some tumours responded well to therapy, and why some patients had serious side effects to the treatment. The results will help inform on selection of therapy for future patients.